netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

The formulary for systemic anti-cancer treatments should be viewed alongside the 'National Cancer Drugs Fund list'

https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/

 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA444 (not recommended): Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
   
Cabozantinib caps (Cometriq)
(Thyroid carcinoma)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance for the treatment of medullary thyroid cancer
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
   
Cabozantinib tabs (Cabometyx)
(Renal cell carcinoma, Hepatocellular carcinoma)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance for the treatment of renal cell carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Crizotinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA drug safety alerts
    • See London Cancer Guidelines for the Treatment of Lung Cancer
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additonally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Dasatinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patient this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA241: CML where treatment with imatinib has failed
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Everolimus (Afinitor)
(Oncology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

DO NOT CONFUSE Afinitor®, Votubia AND Certican AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
    • TA432, 449 and 498 do not apply at NMUH as services not offered.
    • See links below
  • RFL:
    • As per NICE guidance (see below)
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Everolimus (Votubia)
(Angiomyolipoma)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

DO NOT CONFUSE Afinitor®, Votubia AND Certican AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Approved for renal angiomyoplipomas who are at risk of complications but who do not require immediate surgery, and is reserved for patients with multiple AMLs in one or both kidneys and one or more lesions of >3cm in diameter. Restricted to renal consultants in renal genetics specialist clinic only (July 2013)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
Gefitinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology Team ONLY.
    • See links below
  • RFL:
    • Approved for non-small cell lung cancer in line with NICE
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to the treatment of NSCLC with EGFR mutation.
 
Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA374 (not recommended): Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Imatinib tabs
(CML, GIST)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Gilvec for GIST only.

Generic for all other indications.

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
 
Link  NICE TA209 (not recommended): Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425 (not recommended): Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
Lapatinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

Provider notes

  • NMUH:
    • Special Funding Approval required - seek advice from Oncology Pharmacist
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA257 (lapatinib not recommended): Lapatinib or trastuzumab in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
   
Nilotinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Pazopanib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • Approved for metastatic renal cell carcinoma only in line with NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
 
Link  NICE TA215: Pazopanib in renal cell cancer
   
Regorafenib tab
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
Cancer Drugs Fund

See NICE TA for eligibility criteria


Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
    • No restriction stated
  • WH:
    • Non-formulary to WH
 
Link  NICE TA334 (not recommended): Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA514 (not recommended): Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Sorafenib tabs
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • TA178 and TA474 do not apply at NMUH as service is not offered/drug not recommended.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Sunitinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic) 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Vemurafenib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA drug safety updates
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA269: Vemurafenib for treating malignant melanoma
   
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab to top
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Temsirolimus

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
High Cost Medicine
Cancer Drugs Fund
Link  NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA207 (not recommended): Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)
 
Vandetanib tabs

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
High Cost Medicine
Cancer Drugs Fund

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA550 (not recommended): Vandetanib for treating medullary thyroid cancer
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary